<![CDATA[AstraZeneca 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=23332>Tue, 28 Apr 2026 01:21:54 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States]]>https://www.newswire.co.kr/newsRead.php?no=1000655Wed, 13 Nov 2024 11:35:00 +0900<![CDATA[아스트라제네카, 미국 내 R&D 및 제조에 35억달러 투자]]>https://www.newswire.co.kr/newsRead.php?no=1000658Wed, 13 Nov 2024 11:35:00 +0900<![CDATA[Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial]]>https://www.newswire.co.kr/newsRead.php?no=990492Tue, 28 May 2024 14:30:00 +0900<![CDATA[다토포타맙 데룩스테칸, 진행성 비편평 비소세포폐암 환자 대상 TROPION-Lung01 제3상 시험에서 화학요법 대비 임상적으로 의미 있는 전체 생존 개선 입증]]>https://www.newswire.co.kr/newsRead.php?no=990496Tue, 28 May 2024 14:30:00 +0900<![CDATA[AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030]]>https://www.newswire.co.kr/newsRead.php?no=990175Wed, 22 May 2024 14:30:00 +0900<![CDATA[아스트라제네카, 2030년까지 총 매출 800억달러 달성 및 2030년 이후 지속적 성장 포부 공개]]>https://www.newswire.co.kr/newsRead.php?no=990179Wed, 22 May 2024 14:30:00 +0900<![CDATA[AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes]]>https://www.newswire.co.kr/newsRead.php?no=979286Wed, 22 Nov 2023 10:40:00 +0900<![CDATA[아스트라제네카, 헬스테크 기업 에비노바 출범으로 생명과학 분야 혁신, 임상시험 제공, 더 나은 건강 결과를 가속화]]>https://www.newswire.co.kr/newsRead.php?no=979291Wed, 22 Nov 2023 10:40:00 +0900<![CDATA[AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge]]>https://www.newswire.co.kr/newsRead.php?no=976255Fri, 13 Oct 2023 15:15:00 +0900<![CDATA[아스트라제네카, 두 번째 R&D 박사후과정 도전과제에서 전 세계 초기 경력 과학자들의 8가지 혁신적 연구 프로젝트에 자금 제공]]>https://www.newswire.co.kr/newsRead.php?no=976256Fri, 13 Oct 2023 15:15:00 +0900<![CDATA[AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment]]>https://www.newswire.co.kr/newsRead.php?no=974425Thu, 14 Sep 2023 16:19:48 +0900<![CDATA[AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health]]>https://www.newswire.co.kr/newsRead.php?no=969661Thu, 29 Jun 2023 11:40:00 +0900<![CDATA[아스트라제네카, 자연 복원 및 생물 다양성 보전위해 약 5000억원 투자 발표… 기후 변화 대응 및 건강한 인류의 삶을 위해 기여]]>https://www.newswire.co.kr/newsRead.php?no=969702Thu, 29 Jun 2023 11:40:00 +0900<![CDATA[Lung Ambition Alliance, 2025년까지 폐암 환자 5년 생존율 두 배로 향상시킨다는 목표 발표]]>https://www.newswire.co.kr/newsRead.php?no=890913Tue, 09 Jul 2019 09:01:26 +0900<![CDATA[AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials]]>https://www.newswire.co.kr/newsRead.php?no=861306Mon, 11 Dec 2017 09:30:00 +0900<![CDATA[AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial]]>https://www.newswire.co.kr/newsRead.php?no=861299Mon, 11 Dec 2017 09:10:00 +0900<![CDATA[New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases]]>https://www.newswire.co.kr/newsRead.php?no=860063Mon, 20 Nov 2017 11:00:00 +0900<![CDATA[New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer]]>https://www.newswire.co.kr/newsRead.php?no=860060Mon, 20 Nov 2017 10:55:00 +0900<![CDATA[Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib[1]]]>https://www.newswire.co.kr/newsRead.php?no=859795Wed, 15 Nov 2017 13:20:00 +0900<![CDATA[AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification]]>https://www.newswire.co.kr/newsRead.php?no=857925Tue, 17 Oct 2017 11:00:00 +0900<![CDATA[FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB[1]]]>https://www.newswire.co.kr/newsRead.php?no=857841Mon, 16 Oct 2017 11:10:00 +0900<![CDATA[AstraZeneca Presents Tagrisso(osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases]]>https://www.newswire.co.kr/newsRead.php?no=851132Wed, 07 Jun 2017 10:55:00 +0900<![CDATA[Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of Life alongside Improved Progression-Free Survival in Women with BRCA-Mutated Ovarian Cancer]]>https://www.newswire.co.kr/newsRead.php?no=850985Fri, 02 Jun 2017 15:35:00 +0900<![CDATA[Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukaemia]]>https://www.newswire.co.kr/newsRead.php?no=841200Tue, 06 Dec 2016 10:00:00 +0900<![CDATA[Durvalumab Shows Promising Preliminary Early Data in Lung and Head & Neck Cancers]]>https://www.newswire.co.kr/newsRead.php?no=837033Tue, 11 Oct 2016 10:45:00 +0900